Morfouace Michele, Schoot Reineke A, Hol Marinka L F, Minard-Colin Veronique, Kolb Frederic, Bollé Stephanie, Kayembe Matumba T, Gaze Mark N, Sandler Eric, Knops Rutger R G, Merks Johannes H M, Smeele Ludwig E, Indelicato Daniel J, Slater Olga, van Santen Hanneke M
Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Department of Otorhinolaryngology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.
Eur J Endocrinol. 2025 Jan 6;192(1):25-33. doi: 10.1093/ejendo/lvae168.
Survivors of pediatric head and neck rhabdomyosarcoma (HNRMS) are at risk of developing endocrinopathies following local treatment, resulting from radiation damage to the pituitary gland, hypothalamus, or thyroid gland, often at a young age. Our aim was to determine the prevalence of endocrine dysfunction in long-term HNRMS survivors and compare the prevalence of anterior pituitary insufficiency (API) among different local treatment strategies: external beam radiation with photons, external beam radiation with protons, microscopically radical surgery combined with external irradiation, and macroscopic radical surgery combined with brachytherapy.
Head and neck rhabdomyosarcoma survivors treated between 1993 and 2017, with ≥2 years of follow-up, without recurrent disease or secondary malignancy were eligible for this study. The presence of any endocrine dysfunction was assessed cross-sectionally using Common Terminology Criteria of Adverse Events grading, anthropometrics, and biochemical testing. Retrospective chart review was added to this clinical assessment.
Ninety-six survivors with long follow-up time (median, 9 years) were included. Any endocrinopathy was present in 35% of survivors, with 88% having pituitary, 6% peripheral (thyroid), and 6% combined insufficiencies. None had gonadal insufficiency. Growth hormone deficiency was diagnosed in 31 (32%) survivors, with additional pituitary insufficiencies in 12 (39%). In 8%, central precocious puberty preceded API. None of the survivors given brachytherapy had API.
The prevalence of pituitary dysfunction in HNRMS survivors is high, emphasizing the importance of systematic endocrine assessment during follow-up, including pubertal development and growth. Efforts should be made to further reduce extraneous irradiation to endocrine organs to prevent dysfunction later in life.
儿童头颈部横纹肌肉瘤(HNRMS)幸存者在局部治疗后有发生内分泌疾病的风险,这是由于垂体、下丘脑或甲状腺受到辐射损伤所致,且往往发生在年轻时。我们的目的是确定长期HNRMS幸存者内分泌功能障碍的患病率,并比较不同局部治疗策略下垂体前叶功能减退(API)的患病率:光子外照射、质子外照射、显微镜下根治性手术联合外照射以及宏观根治性手术联合近距离放疗。
1993年至2017年间接受治疗的头颈部横纹肌肉瘤幸存者,随访时间≥2年,无疾病复发或继发性恶性肿瘤,符合本研究条件。使用不良事件通用术语标准分级、人体测量学和生化检测对任何内分泌功能障碍的存在进行横断面评估。在此临床评估基础上增加回顾性病历审查。
纳入了96名随访时间长(中位数为9年)的幸存者。35%的幸存者存在任何内分泌疾病,其中88%有垂体功能不全,6%有外周(甲状腺)功能不全,6%有联合功能不全。无人有性腺功能不全。31名(32%)幸存者被诊断为生长激素缺乏,另外12名(39%)有垂体功能不全。8%的患者在API之前出现中枢性性早熟。接受近距离放疗的幸存者均无API。
HNRMS幸存者中垂体功能障碍的患病率很高,强调了随访期间系统内分泌评估的重要性,包括青春期发育和生长情况。应努力进一步减少对内分泌器官的额外照射,以预防日后出现功能障碍。